dpp-4 inhibitors and glp-1 agonists dpp-4_inhibitors [TUSOM DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Court filings and MDL case listings have identified Trulicity among the medications at issue alongside other widely used GLP-1 drugs
Early biosimilar pipelines now coincide with once-weekly and dual-incretin innovations, encouraging payers to re-examine cost-effectiveness thresholds and to broaden indication coverage beyond glycemic control
Additional observations from Phase 2 data include: Mild increases in heart rate, attributed to the glucagon receptor component
In the large SUSTAIN and PIONEER trials, only about 2060% of the CRP reduction was explained by weight and glycaemia
SGLT2 inhibitors and heart failure with preserved ejection fraction
Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al
